Cardiff Oncology Investor Relations Material
Latest events
Study Result
Cardiff Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Cardiff Oncology Inc
Access all reports
Cardiff Oncology Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for various cancers. The company's primary approach involves leveraging PLK1 (Polo-like Kinase 1) inhibition to create novel cancer treatments. Their flagship product, onvansertib, is an oral selective PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics across several clinical programs. These include treatments for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Key slides for Cardiff Oncology Inc
Q4 2023
Cardiff Oncology Inc
Q4 2023
Cardiff Oncology Inc
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
CRDF
Country
🇺🇸 United States